Cardinal Health向SEC支付了880万美元以了结中国FCPA违法行为
基层健康
周五向SEC支付了880万美元，以和解与提供营销服务的中国子公司有关的FCPA违法行为。
在内部行政命令中，
SEC指控Cardinal Health违反了FCPA的账簿和记录以及内部会计控制规定。
位于俄亥俄州都柏林的Cardinal Health
同意向SEC分配540万美元，再加上判决前利息916,887美元，并支付250万美元的民事罚款。
Cardinal
entered the Chinese market in November 2010 when it acquired a company that was later re-branded as Cardinal China.
After it was acquired, Cardinal China
abruptly terminated at least two third-party marketing accounts amid allegations that they had been used to facilitate improper payments.
In one instance, a marketing account it administered for a UK- based pharmaceutical manufacturer was terminated in 2013 after Cardinal’s CEO received an internal report alleging that
Cardinal China employees were using the account to “bribe employees of China’s Center for Disease Control.”
Cardinal China also operated marketing accounts for a European supplier of non-prescription, over-the-counter dermocosmetic products for which Cardinal China was the exclusive distributor in China.
Cardinal employed 2,400 people on the European company’s behalf, the SEC said.
According to the SEC,
Cardinal determined that other marketing accounts should be terminated because of their significant FCPA-related compliance risks, but the company “inaccurately assessed the risks of the arrangements with the dermocosmetic company as minimal” and didn’t apply its full internal accounting controls to those accounts.
As a result, some critical employees didn’t receive FCPA and anti-bribery training, and weren’t properly supervised when they dealt with third parties in China.
The FCPA Blog
https://fcpablog.com/2020/02/28/cardinal-health-pays-sec-8-8-million-to-settle-china-fcpa-offenses/
SEC.gov | SEC Charges Cardinal Health With FCPA Violations